Elevation Point Wealth Partners LLC Purchases 29,900 Shares of Sanofi $SNY

Elevation Point Wealth Partners LLC grew its holdings in Sanofi (NASDAQ:SNY) by 517.4% during the first quarter, Holdings Channel.com reports. The firm owned 35,679 shares of the company’s stock after acquiring an additional 29,900 shares during the quarter. Elevation Point Wealth Partners LLC’s holdings in Sanofi were worth $1,719,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Raymond James Financial Inc. grew its position in Sanofi by 81.3% in the second quarter. Raymond James Financial Inc. now owns 5,879,894 shares of the company’s stock valued at $284,058,000 after purchasing an additional 2,635,867 shares in the last quarter. Capital Research Global Investors bought a new stake in Sanofi during the 4th quarter worth about $79,960,000. Morgan Stanley lifted its position in Sanofi by 20.4% during the 4th quarter. Morgan Stanley now owns 9,102,196 shares of the company’s stock worth $441,093,000 after buying an additional 1,540,271 shares in the last quarter. Franklin Resources Inc. boosted its stake in shares of Sanofi by 29.7% during the 4th quarter. Franklin Resources Inc. now owns 5,100,097 shares of the company’s stock worth $247,151,000 after buying an additional 1,168,339 shares during the last quarter. Finally, BNP Paribas Financial Markets boosted its stake in shares of Sanofi by 422.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 1,062,809 shares of the company’s stock worth $50,165,000 after buying an additional 859,246 shares during the last quarter. Institutional investors and hedge funds own 14.03% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on SNY shares. Argus upgraded Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Morgan Stanley set a $52.00 price target on Sanofi in a research note on Friday, May 1st. Weiss Ratings upgraded Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. BNP Paribas Exane downgraded Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective for the company. in a report on Monday, April 20th. Finally, Citigroup reissued a “neutral” rating on shares of Sanofi in a research note on Monday, April 13th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and ten have given a Hold rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $51.00.

Sanofi Stock Performance

Sanofi stock opened at $43.16 on Monday. Sanofi has a 52 week low of $40.89 and a 52 week high of $52.68. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.22 and a current ratio of 1.01. The stock has a market capitalization of $104.64 billion, a P/E ratio of 12.06, a PEG ratio of 1.07 and a beta of 0.34. The stock has a 50-day simple moving average of $43.68 and a 200 day simple moving average of $45.83.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which was paid on Wednesday, June 3rd. Stockholders of record on Monday, May 4th were paid a dividend of $2.4225 per share. The ex-dividend date was Monday, May 4th. This represents a dividend yield of 559.0%. This is an increase from Sanofi’s previous annual dividend of $2.04. Sanofi’s dividend payout ratio is presently 49.16%.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.